All In Biotech

Free tool

FAERS Monitor: Vanflyta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216993 or its brand name (Vanflyta, Quizartinib Dihydrochloride). Reports on generic versions are filed under their own applications.

Reports

702

Serious

451

64% of reports

Hospitalization

243

Death reported

107

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use79
  • no adverse event71
  • death56
  • nausea50
  • platelet count decreased49
  • pyrexia43
  • febrile neutropenia39
  • fatigue37
  • disease progression35
  • electrocardiogram qt prolonged35
  • infection35
  • product dose omission issue32
  • pneumonia29
  • diarrhoea25
  • white blood cell count decreased25

Reports by year received

View as table
YearReports
20121
20172
20184
201914
20207
202113
20226
202334
2024165
2025239
2026217

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,457 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
electrocardiogram qt prolongedSignal3529.221.1925
febrile neutropeniaSignal3917.613.0597
platelet count decreasedSignal4913.810.5571
no adverse eventSignal7111.79.4693
disease progressionSignal358.96.4238
infectionSignal357.25.2183
white blood cell count decreasedSignal256.94.7121
pyrexiaSignal433.72.884
product dose omission issueSignal323.32.349
off label useSignal792.72.287
pneumoniaSignal292.71.929
death561.91.526
nausea501.91.421
fatigue371.41.04
diarrhoea251.20.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.